The first batch of the COVID-19 vaccine produced at Panacea Biotec’s services at Baddi in Himachal Pradesh might be shipped to Russia’s Gamaleya Center for high quality management
New Delhi: The Russian Direct Investment Fund (RDIF) and Indian drug agency Panacea Biotec on Monday introduced the launch of the manufacturing of the Sputnik V coronavirus vaccine in India.
The first batch of the COVID-19 vaccine produced at Panacea Biotec’s services at Baddi in Himachal Pradesh might be shipped to Russia’s Gamaleya Center for high quality management.
Full-scale manufacturing of the vaccine is anticipated to begin this summer time, RDIF and Panacea Biotec stated in a joint assertion.
As introduced in April, RDIF and Panacea have agreed to supply 100 million doses per 12 months of Sputnik V, it added.
“Launch of production in India in partnership with Panacea Biotec marks an important step in helping the country fight the pandemic,” RDIF chief government Kirill Dmitriev stated.
The manufacturing of Sputnik V helps efforts of India’s authorities to go away behind the acute section of coronavirus as quickly as attainable whereas the vaccine may also be exported at a later stage to assist stop the unfold of the virus in different international locations around the globe, he added.
On the event, Panacea Biotec MD Rajesh Jain stated, “This marks a significant step as we initiate production of Sputnik V. Together with RDIF, we hope to help bring a sense of normalcy back to people across the country and around the world.”
Sputnik V was registered in India beneath the emergency use authorisation process on 12 April, 2021, and vaccination towards coronavirus with the Russian vaccine began on 14 May.